ZTS Stock Analysis: Zoetis | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 30.388m USD | 12M Return: -50.9% | US98978V1035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 489M
EPS Trend: 99.0%
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zoetis Inc. (NYSE: ZTS) is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. It was incorporated in 2012 in connection with its spin-off from Pfizer, and it IPOd on the NYSE in February 2013. The company is classified within the Health Care sector (Pharmaceuticals sub-industry) under GICS, and operates as a large-cap U.S. issuer.
The business is organized around two end markets: companion animals (dogs, cats, and horses) and livestock (cattle, swine, poultry, fish, and sheep). Core product categories include parasiticides, vaccines, dermatology, anti-infectives, pain and sedation products, and other pharmaceuticals. Zoetis sells primarily to veterinarians, livestock producers, and pet owners, with companion animal products generally serving as the higher-margin segment of the animal health industry due to more inelastic demand and insurance-driven spending.
Beyond drugs and vaccines, Zoetis offers point-of-care diagnostics, lab instruments and reagents, rapid immunoassay tests, reference laboratory services, blood glucose monitors, and non-pharmaceutical lines such as nutritionals, biodevices, and genetic testing. The company has a collaboration with Blacksmith Medicines to develop novel antibiotics for animal use, reinforcing its R&D pipeline focus. Zoetis is headquartered in Parsippany, New Jersey.
- Companion animal revenue and margins outpace livestock segment
- New dermatology and pain products like Librela accelerate growth
- Livestock demand tied to global protein consumption trends
| Net Income: 2.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 0.37 > 1.0 |
| NWC/Revenue: 45.13% < 20% (prev 27.25%; Δ 17.88% < -1%) |
| CFO/TA 0.19 > 3% & CFO 2.89b > Net Income 2.62b |
| Net Debt (7.75b) to EBITDA (4.00b): 1.94 < 3 |
| Current Ratio: 3.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (417.7m) vs 12m ago -6.24% < -2% |
| Gross Margin: 70.87% > 18% (prev 70.03%; Δ 0.85% > 0.5%) |
| Asset Turnover: 64.40% > 50% (prev 64.82%; Δ -0.42% > 0%) |
| Interest Coverage Ratio: 14.43 > 6 (EBIT TTM 3.52b / Interest Expense TTM 244.0m) |
| A: 0.28 (Total Current Assets 6.36b - Total Current Liabilities 2.06b) / Total Assets 15.1b |
| B: 0.97 (Retained Earnings 14.7b / Total Assets 15.1b) |
| C: 0.24 (EBIT TTM 3.52b / Avg Total Assets 14.8b) |
| D: 0.26 (Book Value of Equity 3.15b / Total Liabilities 11.9b) |
| Altman-Z'' = 6.92 = AAA |
| DSRI: 1.01 (Receivables 1.57b/1.54b, Revenue 9.52b/9.38b) |
| GMI: 0.99 (GM 70.03% / 70.87%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.01 (Revenue 9.52b / 9.38b) |
| TATA: -0.02 (NI 2.62b - CFO 2.89b) / TA 15.1b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of August 15, 2026, the stock is trading at USD 73.79 with a total of 4,449,233 shares traded. Over the past week, the price has changed by +1.56%, over one month by +0.32%, over three months by -1.56% and over the past year by -50.86%.
Current recommended Stop Loss: 69.80 (which is 5.4% or 1.3 ATR below the current price).
Zoetis has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ZTS.
- StrongBuy: 9
- Buy: 3
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 100.9 | 36.8% |
P/E Trailing = 12.2771
P/E Forward = 12.0627
P/S = 3.1904
P/B = 9.8226
P/EG = 6.7052
Revenue TTM = 9.52b USD
EBIT TTM = 3.52b USD
EBITDA TTM = 4.00b USD
Long Term Debt = 9.05b USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from shortTermDebt, last fiscal year)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 190.0m
Net Debt = 7.75b USD (calculated: Debt 9.43b - CCE 1.68b)
Enterprise Value = 38.1b USD (30.4b + Debt 9.43b - CCE 1.68b)
Interest Coverage Ratio = 14.43 (Ebit TTM 3.52b / Interest Expense TTM 244.0m)
EV/FCF = 16.12x (Enterprise Value 38.1b / FCF TTM 2.37b)
FCF Yield = 6.20% (FCF TTM 2.37b / Enterprise Value 38.1b)
FCF Margin = 24.86% (FCF TTM 2.37b / Revenue TTM 9.52b)
Net Margin = 27.49% (Net Income TTM 2.62b / Revenue TTM 9.52b)
Gross Margin = 70.87% ((Revenue TTM 9.52b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 72.73% (prev 71.66%)
Tobins Q-Ratio = 2.53 (Enterprise Value 38.1b / Total Assets 15.1b)
Interest Expense / Debt = 2.59% (Interest Expense 244.0m / Debt 9.43b)
Taxrate = 20.05% (656.0m / 3.27b)
NOPAT = 2.82b (EBIT 3.52b * (1 - 20.05%))
Current Ratio = 3.08 (Total Current Assets 6.36b / Total Current Liabilities 2.06b)
Debt / Equity = 2.99 (Debt 9.43b / totalStockholderEquity, last quarter 3.15b)
Debt / EBITDA = 1.94 (Net Debt 7.75b / EBITDA 4.00b)
Debt / FCF = 3.28 (Net Debt 7.75b / FCF TTM 2.37b)
Total Stockholder Equity = 3.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.70% (Net Income 2.62b / Total Assets 15.1b)
RoE = 69.25% (Net Income TTM 2.62b / Total Stockholder Equity 3.78b)
RoCE = 27.45% (EBIT 3.52b / Capital Employed (Equity 3.78b + L.T.Debt 9.05b))
RoIC = 22.35% (NOPAT 2.82b / Invested Capital 12.6b)
WACC = 5.15% (E(30.4b)/V(39.8b) * Re(6.10%) + D(9.43b)/V(39.8b) * Rd(2.59%) * (1-Tc(0.20)))
Discount Rate = 6.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.03 | Cagr: -4.09%
[DCF] Terminal Value 76.27% ; FCFF base≈2.31b ; Y1≈2.44b ; Y5≈2.88b
[DCF] Fair Price = 88.49 (EV 44.3b - Net Debt 7.75b = Equity 36.6b / Shares 413.2m; r=8.35% [WACC [floored]]; 5y FCF grow 6.62% → 2.50% )
EPS Correlation: 99.02 | EPS CAGR: 9.41% | SUE: 0.42 | # QB: 0
Revenue Correlation: 94.17 | Revenue CAGR: 4.70% | SUE: -1.04 | # QB: -2
EPS current Quarter (2026-09-30): EPS=1.55 | Chg30d=-16.11% | Revisions=-29% | Analysts=14
EPS current Year (2026-12-31): EPS=6.29 | Chg30d=-8.45% | Revisions=-67% | GrowthEPS=-1.9% | GrowthRev=-2.1%
EPS next Year (2027-12-31): EPS=6.73 | Chg30d=-8.96% | Revisions=-44% | GrowthEPS=+7.1% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -63% (up=2, down=14)